Literature DB >> 25419425

Essential thrombocytosis accompanied by coagulation factor XII deficiency: a case report.

Yan Wang1, Zunsong Wang1, Hong Li1, Kehong Bi1, Chuansheng Zhu1.   

Abstract

Essential thrombocytosis (ET) is a type of myeloproliferative neoplasm with clinical manifestations of thrombosis and hemorrhage, the mechanisms of which remains unclear. Some researches indicated that ET is mainly related to the defect of platelet function and the abnormality of coagulation mechanism. A few reports showed that ET accompanied by acquired hemophilia. However, no evidence of ET with coagulation factor XII deficiency has been published. we here report a case of ET accompanied with coagulation factor XII deficiency, which had clinically significant bleeding tendency.

Entities:  

Keywords:  Essential thrombocytosis; coagulation factor XII deficiency; myeloproliferative disease; von Willebrand disease

Year:  2014        PMID： 25419425      PMCID： PMC4238534     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN： 1940-5901


  11 in total

1.  [Preliminary study on the effects of coagulation factor XII on fibrinolysis].

Authors:  Y Hu; H Wang; J Jiao; Y Wang; W Yu; X Ling
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2000-09

2.  Direct evidence for normalization of platelet function resulting from platelet count reduction in essential thrombocythemia.

Authors:  Argirios E Tsantes; Georgios K Nikolopoulos; Panagiotis Tsirigotis; Katerina Zoi; Athanasios Zomas; Violetta Kapsimali; Petros Kopterides; Spyros Chondropoulos; John Dervenoulas; Georgios Mantzios
Journal:  Blood Coagul Fibrinolysis       Date:  2011-09       Impact factor: 1.276

3.  Acquired hemophilia A in a patient with essential thrombocythemia.

Authors:  Naoki Mori; Kyoichi Totsuka; Noriko Ishimori; Kentaro Yoshinaga; Masanao Teramura; Sanshiro Noguchi; Hideaki Oda; Toshiko Motoji
Journal:  Acta Haematol       Date:  2012-02-01       Impact factor: 2.195

Review 4.  The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.

Authors:  Jan J Michiels; Zwi Berneman; Wilfried Schroyens; Guido Finazzi; Ulrich Budde; Huub H D M van Vliet
Journal:  Semin Thromb Hemost       Date:  2006-09       Impact factor: 4.180

5.  Acquired hemophilia: we now see it with myeloproliferative neoplasms.

Authors:  Marina Kremyanskaya; Louis Aledort
Journal:  Am J Hematol       Date:  2011-02-15       Impact factor: 10.047

6.  Acquired von Willebrand's disease in myelofibrosis and essential thrombocythemia.

Authors:  J Goyal; V V B Reddy; M B Marques
Journal:  Haemophilia       Date:  2013-04-17       Impact factor: 4.287

7.  Should factor XII assays be included in thrombophilia screening?

Authors:  M Winter; M Gallimore; D W Jones
Journal:  Lancet       Date:  1995-07-01       Impact factor: 79.321

8.  JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients.

Authors:  Francesca Palandri; Emanuela Ottaviani; Federica Salmi; Lucia Catani; Nicola Polverelli; Mauro Fiacchini; Giovanni Martinelli; Michele Baccarani; Nicola Vianelli
Journal:  Leuk Lymphoma       Date:  2009-02

9.  Coagulation factor XII Locarno: the functional defect is caused by the amino acid substitution Arg 353-->Pro leading to loss of a kallikrein cleavage site.

Authors:  J K Hovinga; J Schaller; H Stricker; W A Wuillemin; M Furlan; B Lämmle
Journal:  Blood       Date:  1994-08-15       Impact factor: 22.113

10.  ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.

Authors:  Marina Panova-Noeva; Marina Marchetti; Laura Russo; Carmen J Tartari; Anna Leuzzi; Guido Finazzi; Alessandro Rambaldi; Hugo ten Cate; Anna Falanga
Journal:  Thromb Res       Date:  2013-06-02       Impact factor: 3.944
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.